Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long-term remission

Toshiki Terao, Junichiro Yuda, Nobuhiko Yamauchi, Yong Mei Guo, Kaoru Shimada, Masato Sugano, Genichiro Ishii, Yosuke Minami

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Gray zone lymphoma (GZL) is a rare type of B-cell lymphoma characterized by features of both diffuse large B-cell lymphoma and classical Hodgkin lymphoma (cHL). The prognosis of GZL is poorer than that of cHL and mediastinal large B-cell lymphoma. However, an optimal treatment strategy for relapsed/refractory (R/R) GZL has not been established in the clinical setting. The current study reported an excellent clinical response in a patient with R/R CD30-positive GZL who received brentuximab vedotin (BV) maintenance after autologous stem cell transplantation (ASCT). Although the patient was resistant to prior treatments, BV maintenance after ASCT achieved long-term remission. Hence, BV was determined to be a safe and effective therapeutic option for CD30-positive R/R GZL.

Original languageEnglish
Article number125
JournalMolecular and Clinical Oncology
Volume14
Issue number6
DOIs
Publication statusPublished - 2021
Externally publishedYes

Keywords

  • Brentuximab vedotin
  • CD30
  • Gray zone lymphoma
  • Refractory
  • Relapsed

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long-term remission'. Together they form a unique fingerprint.

Cite this